Cargando…

Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance

BACKGROUND: Despite the remarkable success of immunotherapy in treating melanoma, understanding of the underlying mechanisms of resistance remains limited. Emerging evidence suggests that upregulation of tumor-specific major histocompatibility complex-II (tsMHC-II) serves as a predictive marker for...

Descripción completa

Detalles Bibliográficos
Autores principales:	James, Jamaal L, Taylor, Brandie C, Axelrod, Margaret L, Sun, Xiaopeng, Guerin, Lindsey N, Gonzalez-Ericsson, Paula I, Wang, Yu, Sanchez, Violeta, Fahey, Catherine, Sanders, Melinda E, Xu, Yaomin, Hodges, Emily, Johnson, Douglas B, Balko, Justin M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660662/ http://dx.doi.org/10.1136/jitc-2023-007736

Ejemplares similares

Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer
por: Gonzalez-Ericsson, Paula I., et al.
Publicado: (2021)

MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression
por: Franklin, Derek A., et al.
Publicado: (2020)

Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response
por: Taylor, Brandie C., et al.
Publicado: (2022)

MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma
por: Engelhard, Victor H, et al.
Publicado: (2020)

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
por: Minnar, Christine M, et al.
Publicado: (2022)

Optimized combinatorial pMHC class II multimer labeling for precision immune monitoring of tumor-specific CD4 T cells in patients
por: Rockinger, Georg Alexander, et al.
Publicado: (2020)

Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma
por: Wang-Bishop, Lihong, et al.
Publicado: (2020)

Polycomb Repressor Complex 2 in Genomic Instability and Cancer
por: Veneti, Zoe, et al.
Publicado: (2017)

Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment
por: Lin, Weiwei, et al.
Publicado: (2023)

IMMU-30. UPREGULATED T CELL AND INTERFERON-Γ-RELATED GENE EXPRESSION IS ASSOCIATED WITH INCREASED SURVIVAL IN RECURRENT PEDIATRIC HIGH-GRADE GLIOMA
por: Davidson, Tom, et al.
Publicado: (2020)

The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens
por: Steele, J C, et al.
Publicado: (2006)

DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer
por: Luo, Na, et al.
Publicado: (2018)

Albumin and interferon-β fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8+ T cell-mediated antitumor immunity
por: Tseng, Ssu-Hsueh, et al.
Publicado: (2022)

REST–Mediated Recruitment of Polycomb Repressor Complexes in Mammalian Cells
por: Dietrich, Nikolaj, et al.
Publicado: (2012)

Chromatin Sampling—An Emerging Perspective on Targeting Polycomb Repressor Proteins
por: Klose, Robert J., et al.
Publicado: (2013)

Polycomb repressor complex 2 function in breast cancer (Review)
por: Martin, Courtney J., et al.
Publicado: (2020)

Structural heterogeneity of the mammalian polycomb repressor complex in immune regulation
por: Kang, Seok-Jin, et al.
Publicado: (2020)

Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer
por: Axelrod, Margaret L., et al.
Publicado: (2022)

Interferon gamma inhibits CXCL8–CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer
por: Zhang, Mingjie, et al.
Publicado: (2020)

Structural basis for targeting the chromatin repressor Sfmbt to Polycomb response elements
por: Alfieri, Claudio, et al.
Publicado: (2013)

Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck
por: Johnson, Jennifer M, et al.
Publicado: (2023)

Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
por: Laino, Andressa S, et al.
Publicado: (2020)

IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment
por: Desbois, Mélanie, et al.
Publicado: (2020)

Molecular recognition of histone lysine methylation by the Polycomb group repressor dSfmbt
por: Grimm, Clemens, et al.
Publicado: (2009)

Deregulation of polycomb repressor complex 1 modifier AUTS2 in T-cell leukemia
por: Nagel, Stefan, et al.
Publicado: (2016)

C reactive protein impairs adaptive immunity in immune cells of patients with melanoma
por: Yoshida, Tatsuya, et al.
Publicado: (2020)

Domain binding and isotype dictate the activity of anti-human OX40 antibodies
por: Griffiths, Jordana, et al.
Publicado: (2020)

Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
por: Balaji, Aanika, et al.
Publicado: (2021)

Selective requirement for polycomb repressor complex 2 in the generation of specific hypothalamic neuronal subtypes
por: Yaghmaeian Salmani, Behzad, et al.
Publicado: (2022)

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
por: Khushalani, Nikhil I, et al.
Publicado: (2022)

Survivin prevents the polycomb repressor complex 2 from methylating histone 3 lysine 27
por: Jensen, Maja, et al.
Publicado: (2023)

IMMU-06. T-CELL IMMUNOTHERAPY FOR PEDIATRIC BRAIN TUMORS: DIVERSITY IN CELL SURFACE ANTIGEN AND HLA EXPRESSION NECESSITATES A MULTI-PRONGED APPROACH
por: Houke, Haley, et al.
Publicado: (2020)

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer
por: Abdul Sater, Houssein, et al.
Publicado: (2020)

In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
por: Jenner, Adrianne L, et al.
Publicado: (2021)

The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling
por: Meneveau, Max O, et al.
Publicado: (2022)

IMMU-18. FAVORABLE OUTCOME IN REPLICATION REPAIR DEFICIENT HYPERMUTANT BRAIN TUMORS TO IMMUNE CHECKPOINT INHIBITION: AN INTERNATIONAL RRD CONSORTIUM REGISTRY STUDY
por: Bouffet, Eric, et al.
Publicado: (2020)

PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity
por: Koller, Paul, et al.
Publicado: (2023)

Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma
por: Chuntova, Pavlina, et al.
Publicado: (2022)

CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models
por: Ye, Jian, et al.
Publicado: (2023)

Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine
por: Tran, Christine A, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0763ihb7jkaauc51b2447dsgtt